Embryolisse Lait-Crème Fluid
Everything behind the verdicts on this product: the rule that fired for each concern, the three answers and the documents they rest on, every study on the row with the date it was opened, and the versions of the tables that produced them. Nothing here is edited by hand; it is generated from the same records the verdicts are.
The scaleRecommendedGoodSupportingEarly evidenceNot for thisAvoidhow it works
Engine 5.2.0 · rules 0.5.1 · evidence table ev-2026.10-r231 · computed October 13, 2026 · how we decide · the evidence table · the anchors
for Dehydration
Hyaluronic Acid is a reference standard by mechanism for dehydration; this lotion carries it.
A trial-supported active, or a reference standard by mechanism, at a working level; or a first-line active below its studied range.
- Rule
- R5 → Good choice. A supported active (trial-backed, or a reference standard by mechanism); declared at a working strength, or a labelled active or at a plausible but undeclared level.
q1 = supported · q2 = adequate | plausible
Why this rule exists: Trial-supported or guideline-supported active, adequately or plausibly dosed.
Rule R5 decided 9,843 verdicts across the catalog; “Good choice” is the verdict on 10,340 of 45,446. The full register. - Carrying active
- Sodium Hyaluronate
- 1 · Standing
- Supported — its mechanism is established (a reference standard, not a trial result)
- 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
Studied range: 0.1%, from the trials on the row; needs leave-on contact; judge it after about 1 weeks - 3 · Tolerability
- Standard tolerability
- Evidence dots
- Limited evidence
Row checked against its sources on July 17, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- Draelos ZD, Cosmetic Dermatology: Products and Procedures — hyaluronic acid classified as a humectant water-binding agent holding many times its weight in water — reference work
← Back to the verdict All dehydration products → Disclose a concentration or correct a fact →
for Dullness
Hyaluronic Acid has early or mechanistic evidence for dullness — a reasonable bet, not a recommendation; the other actives here are not yet assessed for it.
The lead active has early or mechanistic evidence only, or is present below a working level. A reasonable bet, not a recommendation.
- Rule
- R9 → Unproven. An active with early or mechanistic evidence only; the product’s category job is not a recognised companion to the concern.
q1 = plausible · supportive = false
Why this rule exists: Plausible-tier actives alone do not earn a recommendation, and 'not for this' would overstate the case against them. 'Unproven' with the evidence dots lets the reader judge the bet (added 0.2.0 after the first shadow run put a 10% niacinamide serum at 'not for this' for hyperpigmentation). 0.5.0: the closing clause reads the other heroes — "nothing else here addresses it" only when every other active has a researched 'none' row; "not yet assessed" when that is the truth. Rows whose dots read moderate or better now reach R9p first.
Rule R9 decided 4,156 verdicts across the catalog; “Unproven” is the verdict on 4,156 of 45,446. The full register. - Carrying active
- Sodium Hyaluronate
- 1 · Standing
- Plausible — trials support it
- 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
- 3 · Tolerability
- Standard tolerability
- Evidence dots
- Limited evidence
Row checked against its sources on July 17, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- October 9, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- Benefits of topical hyaluronic acid for skin quality and signs of skin aging: From literature review to clinical evidence — Dermatologic Therapy (2022), opened July 16, 2026
← Back to the verdict All dullness products → Disclose a concentration or correct a fact →
for Compromised Skin Barrier
This formula carries fragrance — a known trigger for compromised skin barrier — so it is not a fit however good its actives are.
The formula carries a known trigger for the concern — fragrance for rosacea, comedogenic esters for acne, fungal triggers for fungal acne — which decides the verdict before any efficacy question.
- Rule
- R1 → Avoid. The formula carries a known trigger for the concern.
q3 = harsh
Why this rule exists: Safety outranks praise (MASTER-PLAN §1.7). A condition-weighted trigger (multiplier ≥ 2 in condition-fit-matrix) decides the verdict before any efficacy question.
Rule R1 decided 1,307 verdicts across the catalog; “Avoid” is the verdict on 1,912 of 45,446. The full register. - Carrying active
- Niacinamide
- 1 · Standing
- Supported — its mechanism is established (a reference standard, not a trial result)
- 2 · Form
- Adequate — concentration not declared; read from the position in the ingredient list
Studied range: 2%, from the trials on the row; needs leave-on contact; judge it after about 8 weeks - 3 · Tolerability
- Carries a trigger — fragrance load
- Evidence dots
- Limited evidence
Row checked against its sources on July 17, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- Moisturizing effects of topical nicotinamide on atopic dry skin — International Journal of Dermatology (2005), opened July 16, 2026
- Two randomized, controlled, comparative studies of the stratum corneum integrity benefits of two cosmetic niacinamide/glycerin body moisturizers vs. conventional body moisturizers — Journal of Drugs in Dermatology (2012), opened July 16, 2026
- Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea — Cutis (2005), opened July 16, 2026
- Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier — British Journal of Dermatology (2000), opened July 16, 2026
← Back to the verdict All compromised skin barrier products → Disclose a concentration or correct a fact →
as a moisturizer
Does what a moisturizer is for: draws in water, softens and smooths.
- Rule
- J2 → Does the job. The category-job reading is 65 or more.
Category job score over the measured features 65–85. - Measured from the label
- draws in water, softens and smooths, seals moisture in, supplies barrier lipids, right weight for the job
- Tolerability
- Standard tolerability
A verdict is Dermington’s assessment of how well a product’s ingredients fit a concern — never a claim about what the product treats. Every rule is public and the same for every product; a brand cannot buy a reading. How we decide · what has changed · disclaimer.